Correspondence 0001104659-23-043790 from MARINUS PHARMACEUTICALS, INC. (MRNS) (CIK 0001267813)
MARINUS PHARMACEUTICALS, INC. (MRNS) (CIK 0001267813)
Date: April 11, 2023 · CIK: 0001267813 · Accession: 0001104659-23-043790
AI Filing Summary & Sentiment
File numbers found in text: 333-271041
Letter
VIA EDGAR Office of Life Sciences Division of Corporation Finance Registration Statement on Form S-3 Filed March 31, 2023 File No. 333-271041 Request for Acceleration of Effective Date
Dear Mr. Buchmiller:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Marinus Pharmaceuticals, Inc. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3 and declare such Registration Statement effective as of 4:00 p.m., Eastern Time, on April 11, 2023, or as soon thereafter as possible.
Please direct any questions or comments concerning this request to Stephen M. Nicolai of Hogan Lovells US LLP at (267) 675-4642. Also, please notify Mr. Nicolai when this request for acceleration has been granted.
Very truly yours,
MARINUS PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm MARINUS PHARMACEUTICALS, INC. 5 Radnor Corporate Center, Suite 500 100 Matsonford Rd Radnor, PA 19087 April 11, 2023 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Tim Buchmiller Re: Marinus Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed March 31, 2023 File No. 333-271041 Request for Acceleration of Effective Date Dear Mr. Buchmiller: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Marinus Pharmaceuticals, Inc. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3 and declare such Registration Statement effective as of 4:00 p.m., Eastern Time, on April 11, 2023, or as soon thereafter as possible. Please direct any questions or comments concerning this request to Stephen M. Nicolai of Hogan Lovells US LLP at (267) 675-4642. Also, please notify Mr. Nicolai when this request for acceleration has been granted. Very truly yours, MARINUS PHARMACEUTICALS, INC. By: /s/ Steven Pfanstiel Name: Steven Pfanstiel Title: Chief Financial Officer, Chief Operating Officer and Treasurer